1.580USD-2.35%Mkt Cap: 67.20M USDP/E: —Last update: 2026-06-01
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generat…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap67.20M USD
Enterprise Value-26.84M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.91M USD
Revenue/Share—
Last Price1.580 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees74
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.82
PEG—
EV/EBITDA0.33
EV/Revenue—
P/S—
P/B0.65
EPS (TTM)-2.00
EPS (Forward)-1.95
52W Range
1.05021% of range3.560
52W High3.560 USD
52W Low1.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.24%
ROA-60.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-63.66M USD
CapEx (TTM)1.67M USD
FCF Margin—
FCF Yield-58.46%
Net Debt-95.32M USD
Net Debt/EBITDA1.18
Balance Sheet
Debt/Equity0.02
Current Ratio8.98
Quick Ratio8.84
Book Value/Sh2.465 USD
Cash/Share2.283 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)11.50 USD
Target Range7.000 USD – 19.00 USD
# Analysts6
Ownership
Shares Out.42.80M
Float27.97M
Insiders15.55%
Institutions47.07%
Short Interest
Short Ratio3.1d
Short % Float8.71%
Short % Out.5.83%
Shares Short2.50M
Short (prev mo.)2.39M
Technical
SMA 501.727 (-8.5%)
SMA 2001.842 (-14.2%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)707.89K
Avg Vol (10d)510.40K
Technical Indicators
RSI (14)40.0
MACD-0.0437
MACD Signal-0.0089
MACD Hist.-0.0348
BB Upper2.214 USD
BB Middle1.850 USD
BB Lower1.487 USD
BB Width39.30%
ATR (14)0.1197 USD
Vol Ratio (20d)0.52x